BEIJING – The medical technology landscape in China is undergoing a profound transformation, forcing multinational corporations to adapt or reconsider their commitments. The speculated review of GE Healthcare's China business highlights the intense pressure from domestic competition and an unrelenting policy environment focused on cost containment.

The core challenge is the nationwide rollout of the Volume-Based Procurement (VBP) scheme. This policy has made it impossible to sustain previous price levels for mid- to low-end products, leading to a swift replacement by domestic alternatives. The effects are stark across all segments. In orthopedics, giants like Johnson & Johnson and Smith & Nephew have seen their businesses pressured. In IVD, the comprehensive 28-province procurement for chemical发光 reagents in 2024, coupled with lower testing fees, has left little room for foreign players to maneuver, resulting in double-digit declines for Roche and bioMérieux.

Imaging, once a bastion of MNC strength, is not immune. Companies now face extended provincial tender cycles, order delays, and heightened tariff risks, on top of the lingering effects of an anti-corruption campaign in the healthcare sector.

In response, multinationals are pursuing divergent paths, creating a fragmented strategic map:

1. Retreat: Companies like Coloplast have announced significant layoffs and a scaling back of their China operations, citing underperformance and VBP-driven price cuts of 30-40%.

2. Defend: Others are fighting to stay on the shelf at all costs. Boston Scientific and Cordis have won tenders with drastic price cuts exceeding 85%, prioritizing market volume over profitability.

3. Localize: GE Healthcare represents a third path: deep localization. By establishing seven factories and developing products like the domestically-led "Hua" series ultrasound—with over 60,000 units shipped globally—the company is leveraging Chinese manufacturing and R&D to remain competitive.

This tripartite response indicates that the Chinese market is maturing. The easy growth is gone, replaced by a complex environment where success is no longer guaranteed. For those choosing to stay, the formula for survival is becoming clear. It hinges on the ability to continuously innovate with clinically relevant products and to integrate deeply into the medical ecosystem through robust physician training and academic support programs. As one industry veteran noted, “The environment is tough, but the ultimate winners will be those who master product innovation, physician education, and academic development.” Navigating this period of adjustment is the new reality for every player aiming to remain at the table in the world's largest healthcare market.

——

GE IS215ACLEH1BB

GE IS215WEMAH1

GE IC693CMM321-JJ

———————————————————————————————————————————————————————————————————————

Xingruijia

Original factory direct supply, quality assurance - GE module professional supplier

Consult now to obtain the latest technical information and quotation for GE modules!

·Manager: Jinny                                         ·E-mail: sales1@xrjdcs.com     

·Tel: + 86-15359273791（WhatsApp）   ·Wechat: + 86-15359273791

————————————————————————————————————————————————————————————————————————